Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors for the survival of patients with papillary renal cell carcinoma after surgical management

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

To examine the possible prognostic factors in patients with type 1 and type 2 papillary renal cell carcinoma (pRCC) after surgical management and to identify the independent predictive factors of the prognosis.

Methods

From 2010 to 2017, 1405 patients underwent surgery for renal cell carcinoma, of whom 114 had type 1 or type 2 pRCC and follow-up data were available for 88 patients. Clinicopathological and prognostic parameters were compared between type 1 and type 2 pRCC. Possible prognostic factors were retrospectively analyzed by univariate and multivariate analyses with Cox regression.

Results

The study included 63 males and 25 females with a mean age of 54.27 ± 12.91. 53 patients were diagnosed by regular physical examination and others presented with hematuria or lumbago. 53 (60.2%) underwent radical nephrectomy and 35 (39.8%) underwent nephron sparing surgery. After a mean follow-up of 46.08 ± 22.65 months, 16 patients died of pRCC metastasis and the 5-year disease-specific survival was 79.3%. The comparison of the 39 (44.3%) type 1 and 49 (55.7%) type 2 pRCCs revealed that type 2 pRCC had significantly higher grade and worse prognosis. Univariate analysis showed that symptomatic diagnosis, type, grade, and tumor stage were prognostic factors. Multivariate analysis identified that type and tumor stage were independent factors of the prognosis.

Conclusions

Pathological type and tumor stage could serve as independent factors for the prognosis of patients with pRCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Connor Wells J, Donskov F, Fraccon AP, et al. Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Med. 2017;6:902–9. https://doi.org/10.1002/cam4.1048.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ren W, Xue B, Qu J, Liu L, Li C, Zu X. Localized chromophobe renal cell carcinoma: preoperative imaging judgment and laparoscopic simple enucleation for treatment. Int Braz J Urol. 2018;44:922–32. https://doi.org/10.1590/S1677-5538.IBJU.2017.0519.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537–44.

    CAS  PubMed  Google Scholar 

  4. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–45. https://doi.org/10.1056/NEJMoa1505917.

    Article  CAS  Google Scholar 

  5. Warrick JI, Tsodikov A, Kunju LP, et al. Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. Hum Pathol. 2014;45:1139–46. https://doi.org/10.1016/j.humpath.2014.02.004.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68e73.

    Article  Google Scholar 

  7. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163e72.

    Google Scholar 

  8. Steffens S, Janssen M, Roos FC, et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma–a multicentre study. Eur J Cancer. 2012;48:2347–52. https://doi.org/10.1016/j.ejca.2012.05.002.

    Article  PubMed  Google Scholar 

  9. Ledezma RA, Negron E, Paner GP, et al. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016;34:687–93. https://doi.org/10.1007/s00345-015-1692-3.

    Article  PubMed  Google Scholar 

  10. Ricketts CJ, De Cubas AA, Fan H, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018;3(23):313–26. https://doi.org/10.1016/j.celrep.2018.03.075.

    Article  CAS  Google Scholar 

  11. Giles RH, Choueiri TK, Heng DY, et al. Recommendations for the management of rare kidney cancers. Eur Urol. 2017;72:974–83. https://doi.org/10.1016/j.eururo.2017.06.040.

    Article  PubMed  Google Scholar 

  12. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007;69:230–5.

    Article  PubMed  Google Scholar 

  13. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–63.

    Article  CAS  PubMed  Google Scholar 

  14. Sobin LH, Gospodarowicz MK, Wittekind C, editors. The TNM classification of malignant tumors. 7th ed. Wiley-Blackwell: International Union Against Cancer; 2009.

    Google Scholar 

  15. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193e205.

    Article  Google Scholar 

  16. Rao Q, Chen JY, Wang JD, et al. Renal cell carcinoma in children and young adults: clinicopathological, immuno-histochemical, and VHL gene analysis of 46 cases with follow-up. Int J Surg Pathol. 2011;19:170–9.

    Article  PubMed  Google Scholar 

  17. Courthod G, Tucci M, Di Maio M, et al. Papillary renal cell carcinoma: a review of the current therapeutic landscape. Crit Rev Oncol Hematol. 2015;96:100–12.

    Article  PubMed  Google Scholar 

  18. Kuroda N, Toi M, Hiroi M, et al. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2003;18:487–94.

    CAS  PubMed  Google Scholar 

  19. Mejean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol. 2003;170:764–7.

    Article  PubMed  Google Scholar 

  20. Gargouri MM, Ayari Y, Ben CM, et al. Clinical and pathological features of papillary renal cell carcinoma and prognostic value of its type-1 and type-2 subtypes. Afr J Urol. 2016;22:149–52.

    Article  Google Scholar 

  21. Noon AP, Vlatković N, Polański R, et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets. Cancer. 2010;116:780–90.

    Article  CAS  PubMed  Google Scholar 

  22. Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183:1309–15. https://doi.org/10.1016/j.juro.2009.12.035.

    Article  PubMed  Google Scholar 

  23. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;20(23):2763–71.

    Article  Google Scholar 

  24. Delahunt B, Eble JN, McCredie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590–5.

    Article  CAS  PubMed  Google Scholar 

  25. Wahlgren T, Harmenberg U, Sandström P, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). Br J Cancer. 2013;108:1541–9. https://doi.org/10.1038/bjc.2013.119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Li P, Wong YN, Armstrong K, et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med. 2016;5:169–81. https://doi.org/10.1002/cam4.574.

    Article  PubMed  Google Scholar 

  27. Escudier B, Molinie V, Bracarda S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer. 2016;69:226–35. https://doi.org/10.1016/j.ejca.2016.08.004.

    Article  CAS  PubMed  Google Scholar 

  28. Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Ann Oncol. 2015;26:1123–8. https://doi.org/10.1093/annonc/mdv149.

    Article  CAS  PubMed  Google Scholar 

  29. Kim KH, You D, Jeong IG, et al. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus. BJU Int. 2012;110:E673–E678678. https://doi.org/10.1111/j.1464-410X.2012.11498.x.

    Article  PubMed  Google Scholar 

  30. Ha YS, Chung JW, Choi SH, et al. Korean Renal Cell Carcinoma Study Group. Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1 and 2 Using the Korean Renal Cell Carcinoma Database. Clin Genitourin Cancer. 2017;15:e181–6.

  31. Bigot P, Bernhard JC, Gill IS, et al. The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. World J Urol. 2016;34:347–52.

    Article  PubMed  Google Scholar 

  32. Zucchi A, Novara G, Costantini E, et al. Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma. BJU Int. 2012;109:1140–6.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Key R&D Program of China (2016YFC0902603) and the National Natural Science Foundation of China (81572523).

Author information

Authors and Affiliations

  1. Department of Urology, Xiangya Hospital, Central South University, Changsha, 410008, China

    W. Ren, X. Gao, X. Zhang, J. Hu, H. Li & X. Zu

Authors
  1. W. Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X. Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X. Zu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. Zu.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ren, W., Gao, X., Zhang, X. et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma after surgical management. Clin Transl Oncol 22, 725–733 (2020). https://doi.org/10.1007/s12094-019-02181-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-019-02181-0

Keywords

Search

Navigation